Shattuck Labs, Inc. Proceeds from Sale and Maturity of Debt Securities, Available-for-sale
Shattuck Labs, Inc. (STTK) reported Proceeds from Sale and Maturity of Debt Securities, Available-for-sale of $23.91 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities · last filed 2026-08-11
- Shattuck Labs, Inc. proceeds from sale and maturity of debt securities, available-for-sale for the quarter ending 2026-06-30 was -$1.00K.
- Shattuck Labs, Inc. proceeds from sale and maturity of debt securities, available-for-sale for the quarter ending 2026-03-31 was $23.91M, a 53.30% increase year-over-year.
- Shattuck Labs, Inc. proceeds from sale and maturity of debt securities, available-for-sale for the quarter ending 2025-12-31 was $20.00M, a 35.48% decline year-over-year.
- Shattuck Labs, Inc. proceeds from sale and maturity of debt securities, available-for-sale for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Shattuck Labs, Inc. proceeds from sale and maturity of debt securities, available-for-sale for fiscal 2025 was $35.60M, a 58.17% decline from fiscal 2024.
- Shattuck Labs, Inc. proceeds from sale and maturity of debt securities, available-for-sale for fiscal 2024 was $85.10M, a 55.44% decline from fiscal 2023.
- Shattuck Labs, Inc. proceeds from sale and maturity of debt securities, available-for-sale for fiscal 2023 was $191.00M, a 1.20% decline from fiscal 2022.
- Shattuck Labs, Inc. proceeds from sale and maturity of debt securities, available-for-sale for fiscal 2022 was $193.32M, a 4.09% decline from fiscal 2021.
| Period end | Proceeds from Sale and Maturity of Debt Securities, Available-for-sale 3 month | Proceeds from Sale and Maturity of Debt Securities, Available-for-sale 6 month | Proceeds from Sale and Maturity of Debt Securities, Available-for-sale 9 month | Proceeds from Sale and Maturity of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $23.91M 10-Q · filed 2026-08-11 | $43.91M derived: sum of 3 quarters · filed 2026-08-11 | $43.91M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $23.91M 10-Q · filed 2026-05-07 | $43.91M derived: sum of 2 quarters · filed 2026-05-07 | $43.91M derived: sum of 3 quarters · filed 2026-05-07 | $43.91M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $20.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $20.00M derived: sum of 2 quarters · filed 2026-03-05 | $20.00M derived: sum of 3 quarters · filed 2026-08-11 | $35.60M 10-K · filed 2026-03-05 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2026-08-11 | $15.60M 10-Q · filed 2025-11-06 | $46.60M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $15.60M 10-Q · filed 2026-08-11 | $46.60M derived: sum of 3 quarters · filed 2026-08-11 | $75.70M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $15.60M 10-Q · filed 2026-05-07 | $46.60M derived: sum of 2 quarters · filed 2026-05-07 | $75.70M derived: sum of 3 quarters · filed 2026-05-07 | $95.70M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $31.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $60.10M derived: sum of 2 quarters · filed 2026-03-05 | $80.10M derived: sum of 3 quarters · filed 2026-03-05 | $85.10M 10-K · filed 2026-03-05 |
| 2024-09-30 | $29.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $49.10M derived: sum of 2 quarters · filed 2025-11-06 | $54.10M 10-Q · filed 2025-11-06 | $114.90M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $20.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $25.00M 10-Q · filed 2025-08-14 | $85.80M derived: sum of 3 quarters · filed 2025-08-14 | $131.25M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $5.00M 10-Q · filed 2025-05-01 | $65.80M derived: sum of 2 quarters · filed 2025-05-01 | $111.25M derived: sum of 3 quarters · filed 2025-05-01 | $150.80M derived: sum of 4 quarters · filed 2025-05-01 |
| 2023-12-31 | $60.80M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $106.25M derived: sum of 2 quarters · filed 2025-03-27 | $145.80M derived: sum of 3 quarters · filed 2025-03-27 | $191.00M 10-K · filed 2025-03-27 |
| 2023-09-30 | $45.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $85.00M derived: sum of 2 quarters · filed 2024-11-14 | $130.20M 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $39.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $84.74M 10-Q · filed 2024-08-01 | ||
| 2023-03-31 | $45.20M 10-Q · filed 2024-05-02 | |||
| 2022-12-31 | $193.32M 10-K · filed 2024-02-29 | |||
| 2021-12-31 | $66.60M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $126.60M derived: sum of 2 quarters · filed 2023-02-23 | $186.58M derived: sum of 3 quarters · filed 2023-02-23 | $201.57M 10-K · filed 2023-02-23 |
| 2021-09-30 | $60.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $119.98M derived: sum of 2 quarters · filed 2021-11-09 | $134.97M 10-Q · filed 2021-11-09 | $141.30M derived: sum of 4 quarters · filed 2022-03-15 |
| 2021-06-30 | $59.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $74.97M 10-Q · filed 2021-08-12 | $81.30M derived: sum of 3 quarters · filed 2022-03-15 | $94.22M derived: sum of 4 quarters · filed 2022-03-15 |
| 2021-03-31 | $15.00M 10-Q · filed 2021-05-10 | $21.32M derived: sum of 2 quarters · filed 2022-03-15 | $34.25M derived: sum of 3 quarters · filed 2022-03-15 | $43.05M derived: sum of 4 quarters · filed 2022-03-15 |
| 2020-12-31 | $6.33M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $19.25M derived: sum of 2 quarters · filed 2022-03-15 | $28.05M derived: sum of 3 quarters · filed 2022-03-15 | $37.59M 10-K · filed 2022-03-15 |
| 2020-09-30 | $12.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $21.73M derived: sum of 2 quarters · filed 2021-11-09 | $31.27M 10-Q · filed 2021-11-09 | $39.78M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | $8.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $18.34M 10-Q · filed 2021-08-12 | $26.85M derived: sum of 3 quarters · filed 2021-08-12 | |
| 2020-03-31 | $9.54M 10-Q · filed 2021-05-10 | $18.05M derived: sum of 2 quarters · filed 2021-05-10 | ||
| 2019-12-31 | $8.51M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $41.15M 10-K · filed 2021-03-16 | ||
| 2019-09-30 | $32.64M 10-Q · filed 2020-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |